atezolizumab + selicrelumab + bevacizumab

Atezolizumab + selicrelumab + bevacizumab is an investigational **combination therapy** composed of three biologic agents with complementary immunomodulatory and anti-angiogenic mechanisms, studied for the treatment of solid tumors including hepatocellular carcinoma and other cancers. - **Atezolizumab** is a humanized IgG1 monoclonal antibody targeting programmed death-ligand 1 (**PD-L1**), blocking its interaction with PD-1 and B7.1, thereby enhancing T-cell activity and disrupting tumor immune evasion. - **Selicrelumab** is an agonist antibody targeting CD40, a co-stimulatory protein found on antigen-presenting cells, leading to enhanced dendritic cell activation, T-cell priming, and adaptive immune response against tumors. - **Bevacizumab** is a recombinant humanized monoclonal antibody targeting vascular endothelial growth factor A (**VEGF-A**), inhibiting angiogenesis and tumor blood vessel formation, starving the tumor of nutrients and oxygen essential for growth and metastasis. This combination is used in clinical trials to explore synergistic anti-tumor immune responses and anti-angiogenic effects, frequently in patients with advanced solid malignancies.

Other names

atezolizumab + selicrelumab + bevacizumab